Scoop: Mar­tin Shkre­li bats back a coup at Tur­ing, new board con­sid­ers a sale of as­sets

Mar­tin Shkre­li had a lit­tle busi­ness to at­tend to be­fore his fraud tri­al got start­ed in Brook­lyn to­day.

In a show­down last week with chief sci­en­tist and CEO Eliseo Sali­nas, Shkre­li hand­i­ly or­ches­trat­ed a sweep of the board at Tur­ing Phar­ma­ceu­ti­cals, gain­ing the elec­tion of 5 new board mem­bers — a group that in­cludes sev­er­al ex­ec­u­tives with close busi­ness ties to Shkre­li. And Tur­ing says in a state­ment that it will fol­low up on on­go­ing ne­go­ti­a­tions aimed at sell­ing the biotech’s stock and as­sets, which are topped by Dara­prim.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.